macitentan 10 mg
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Conditions
Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Trial Timeline
Jan 8, 2019 → Jun 29, 2020
NCT ID
NCT03809650About macitentan 10 mg
macitentan 10 mg is a phase 3 stage product being developed by BML, Inc. for Chronic Thromboembolic Pulmonary Hypertension (CTEPH). The current trial status is terminated. This product is registered under clinical trial identifier NCT03809650. Target conditions include Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03809650 | Phase 3 | Terminated |
Competing Products
20 competing products in Chronic Thromboembolic Pulmonary Hypertension (CTEPH)